Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Quick Stats
Jan 30, 202641.2
AI Score
HOLD0.72
Volume Ratio
Dec 03, 2025
Next Earnings
12
+ve Days (30d)
17
-ve Days (30d)
KAPA Stock Summary
Last updated Jan 30, 2026
KAPA is currently trading at $0.6644, positioned below its 200-day moving average of $0.92, suggesting bearish momentum. The stock has a 52-week range of $0.4 to $2.11.
Technical Analysis: The 50-day moving average stands at $0.78, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 35.451, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.058, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates KAPA at 41.2/100 with a HOLD recommendation.
KAPA (Kairos Pharma, Ltd.) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 35.451 |
| CMF (20) | -0.058 |
| ROC (10) | -25.348 |
| ADX (14) | 20.99 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.034 |
| AROONOSC (14) | -100.0 |
| WILLAMS %R (14) | -90.685 |
| MFI (14) | 20.396 |
KAPA Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
KAPA Price vs Max Options Open Interest
KAPA Max Change In Options Open Interest
KAPA Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KAPA Daily Out of Money Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KAPA Daily In the Money Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KAPA Most Active Options by Volume(near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Kairos Pharma, Ltd. is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
KAPA Moving Averages Analysis
KAPA (Kairos Pharma, Ltd.) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 0.76 |
| 20 | 0.8 |
| 30 | 0.78 |
| 50 | 0.78 |
| 100 | 0.99 |
| 200 | 0.92 |
KAPA Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 14.0 million |
| Earnings/Share ($) | -0.31 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.2 |
| EPS Estimate Next Year ($) | -0.33 |
| WallStreet Target Price ($) | 8.3333 |
| Most Recent Quarter |